Work

Susceptibility of RUNX1 promoter rs2071029 polymorphism to adjuvant chemotherapy-induced neutropenia in CRC

Year: 2025

Type: article

Abstract: Aim To investigate the susceptibility of Runt-related transcription factor 1 (RUNX1) promoter polymorphism to adjuvant chemotherapy-induced neutropenia (CIN) of colorectal cancer (CRC).Methods RUNX1 promoter polymorphisms rs2071029 and rs12626613 were genotyped by SnaPshot genotyping and Sanger sequencing. The association of rs2071029 and CIN in 204 CRC patients was analyzed using chi-square test and multivariate logistic regression model. The impact of rs2071029 polymorphism on RUNX1 promoter activity was analyzed by luciferase assay.Results Rs2071029 and rs12626613 loci were in strong linkage disequilibrium (D ’ = 0.957. r2 = 0.878). Compared with rs2071029 CC genotype, TT (OR = 0.250, 95% CI: 0.101∼0.617) had a decreased risk of severe CIN. Compared with mFOLFOX6,and baseline neutrophil counts 2–4 × 109/L, Xelox (OR = 0.169, 95% CI: 0.054∼0.531) and >4 × 109/L(OR = 0.446 95% CI: 0.209∼0.952) had a decreased risk of severe CIN, respectively. Rs2071029T promoter activity was significantly higher than that of rs2071029C promoter (p = 0.014). Stratified analyses revealed that the protective effect of the rs2071029 TT was more pronounced in patients over 60 years (OR = 0.139, 95% CI: 0.031–0.622) and stage II cases (OR = 0.117, 95% CI: 0.018–0.745).Conclusion RUNX1 promoter rs2071029 polymorphism could be useful as an independent biomarker for CIN in CRC.

Source: Biomarkers in Medicine

DOI: 10.1080/17520363.2025.2516996